|
1
|
Zöller M: Tetraspanins: push and pull in
suppressing and promoting metastasis. Nat Rev Cancer. 9:40–55.
2009.PubMed/NCBI
|
|
2
|
Romanska HM and Berditchevski F:
Tetraspanins in human epithelial malignancies. J Pathol. 223:4–14.
2011. View Article : Google Scholar
|
|
3
|
Hemler ME: Targeting of tetraspanin
proteins - potential benefits and strategies. Nat Rev Drug Discov.
7:747–758. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hemler ME: Tetraspanin proteins mediate
cellular penetration, invasion and fusion events and define a novel
type of membrane microdomain. Annu Rev Cell Dev Biol. 19:397–422.
2003. View Article : Google Scholar
|
|
5
|
Boucheix C and Rubinstein E: Tetraspanins.
Cell Mol Life Sci. 58:1189–1205. 2001. View Article : Google Scholar
|
|
6
|
Boucheix C, Soria C, Mirshahi M, et al:
Characteristics of platelet aggregation induced by the monoclonal
antibody ALB6 (acute lymphoblastic leukemia antigen p 24).
Inhibition of aggregation by ALB6Fab. FEBS Lett. 161:289–295. 1983.
View Article : Google Scholar
|
|
7
|
Kersey JH, LeBien TW, Abramson CS, Newman
R, Sutherland R and Greaves M: P-24: a human leukemia-associated
and lymphohemopoietic progenitor cell surface structure identified
with monoclonal antibody. J Exp Med. 153:726–731. 1981. View Article : Google Scholar
|
|
8
|
Ikeyama S, Koyama M, Yamaoko M, Sasada R
and Miyake M: Suppression of cell motility and metastasis by
transfection with human motility-related protein (MRP-1/CD9) DNA. J
Exp Med. 177:1231–1237. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miyake M, Koyama M, Seno M and Ikeyama S:
Identification of the motility-related protein (MRP-1), recognized
by monoclonal antibody M31-15, which inhibits cell motility. J Exp
Med. 174:1347–1354. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oritani K, Aoyama K, Tomiyama Y, Kincade
PW and Matsuzawa Y: Stromal cell CD9 and the differentiation of
hematopoietic stem/progenitor cells. Leuk Lymphoma. 38:147–152.
2000.PubMed/NCBI
|
|
11
|
Miyake M, Nakano K, Itoi SI, Koh T and
Taki T: Motility-related protein-1 (MRP-1/CD9) reduction as a
factor of poor prognosis in breast cancer. Cancer Res.
56:1244–1249. 1996.PubMed/NCBI
|
|
12
|
Mori M, Mimori K, Shiraishi T, et al:
Motility related protein 1 (MRP1/CD9) expression in colon cancer.
Clin Cancer Res. 4:1507–1510. 1998.PubMed/NCBI
|
|
13
|
Higashiyama M, Doi O, Kodama K, et al:
Immunohistochemically detected expression of motility-related
protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to
prognosis. Int J Cancer. 74:205–211. 1997. View Article : Google Scholar
|
|
14
|
De Bruyne E, Bos TJ, Asosingh K, et al:
Epigenetic silencing of the tetraspanin CD9 during disease
progression in multiple myeloma cells and correlation with
survival. Clin Cancer Res. 14:2918–2926. 2008.PubMed/NCBI
|
|
15
|
De Bruyne E, Andersen TL, De Raeve H, et
al: Endothelial cell-driven regulation of CD9 or motility-related
protein-1 expression in multiple myeloma cells within the murine
5T33MM model and myeloma patients. Leukemia. 20:1870–1879.
2006.
|
|
16
|
Fan J, Zhu GZ and Niles RM: Expression and
function of CD9 in melanoma cells. Mol Carcinog. 49:85–93.
2010.PubMed/NCBI
|
|
17
|
Sauer G, Windisch J, Kurzeder C, Heilmann
V, Kreienberg R and Deissler H: Progression of cervical carcinomas
is associated with down-regulation of CD9 but strong local
re-expression at sites of transendothelial invasion. Clin Cancer
Res. 9:6426–6431. 2003.
|
|
18
|
Hori H, Yano S, Koufuji K, Takeda J and
Shirouzu K: CD9 expression in gastric cancer and its significance.
J Surg Res. 117:208–215. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Horváth G, Serru V, Clay D, Billard M,
Boucheix C and Rubinstein E: CD19 is linked to the
integrin-associated tetraspans CD9, CD81 and CD82. J Biol Chem.
273:30537–30543. 1998.PubMed/NCBI
|
|
20
|
Stipp CS, Orlicky D and Hemler ME: FPRP, a
major highly stoichiometric, highly specific CD81- and
CD9-associated protein. J Biol Chem. 276:4853–4862. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Berditchevski F: Complexes of tetraspanins
with integrins: more than meets the eye. J Cell Sci. 114:4143–4151.
2001.PubMed/NCBI
|
|
22
|
Miyake M, Nakano K, Ieki Y, et al:
Motility related protein 1 (MRP-1/CD9) expression: inverse
correlation with metastases in breast cancer. Cancer Res.
55:4127–4131. 1995.PubMed/NCBI
|
|
23
|
Cajot JF, Sordat I, Silvestre T and Sordat
B: Differential display cloning identifies motility-related protein
(MRP1/CD9) as highly expressed in primary compared to metastatic
human colon carcinoma cells. Cancer Res. 57:2593–2597. 1997.
|
|
24
|
Mimori K, Kataoka A, Yoshinaga K, et al:
Identification of molecular markers for metastasis-related genes in
primary breast cancer cells. Clin Exp Metastasis. 22:59–67. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kischel P, Bellahcene A, Deux B, et al:
Overexpression of CD9 in human breast cancer cells promotes the
development of bone metastases. Anticancer Res. 32:5211–5220.
2012.PubMed/NCBI
|
|
26
|
Erovic BM, Pammer J, Hollemann D, et al:
Motility-related protein-1/CD9 expression in head and neck squamous
cell carcinoma. Head Neck. 25:848–857. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Longo N, Yáñez-Mó M, Mittelbrunn M, et al:
Regulatory role of tetraspanin CD9 in tumor-endothelial cell
interaction during transendothelial invasion of melanoma cells.
Blood. 98:3717–3726. 2001. View Article : Google Scholar
|
|
28
|
Klein-Soyer C, Azorsa DO, Cazenave JP and
Lanza F: CD9 participates in endothelial cell migration during in
vitro wound repair. Arterioscler Thromb Vasc Biol. 20:360–369.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Iwasaki T, Takeda Y, Maruyama K, et al:
Deletion of tetraspanin CD9 diminishes lymphangiogenesis in vivo
and in vitro. J Biol Chem. 288:2118–2131. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kamisasanuki T, Tokushige S, Terasaki H,
et al: Targeting CD9 produces stimulus-independent antiangiogenic
effects predominantly in activated endothelial cells during
angiogenesis: a novel antiangiogenic therapy. Biochem Biophys Res
Commun. 413:128–135. 2011. View Article : Google Scholar
|
|
31
|
Hong IK, Kim YM, Jeoung DI, Kim KC and Lee
H: Tetraspanin CD9 induces MMP-2 expression by activating p38 MAPK,
JNK and c-Jun pathways in human melanoma cells. Exp Mol Med.
37:230–239. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Osenkowski P, Toth M and Fridman R:
Processing, shedding and endocytosis of membrane type 1-matrix
metalloproteinase (MT1-MMP). J Cell Physiol. 200:2–10. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lafleur MA, Xu D and Hemler ME:
Tetraspanin proteins regulate membrane type-1 matrix
metalloproteinase-dependent pericellular proteolysis. Mol Biol
Cell. 20:2030–2040. 2009. View Article : Google Scholar
|
|
34
|
Richardson MM, Jennings LK and Zhang XA:
Tetraspanins and tumor progression. Clin Exp Metastasis.
28:261–270. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang CL, Ueno M, Liu D, et al: MRP-1/CD9
gene transduction regulates the actin cytoskeleton through the
downregulation of WAVE2. Oncogene. 25:6480–6488. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Takenawa T and Suetsugu S: The WASP-WAVE
protein network: connecting the membrane to the cytoskeleton. Nat
Rev Mol Cell Biol. 8:37–48. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ono M, Handa K, Sonnino S, Withers DA,
Nagai H and Hakomori S: GM3 ganglioside inhibits CD9-facilitated
haptotactic cell motility: coexpression of GM3 and CD9 is essential
in the downregulation of tumor cell motility and malignancy.
Biochemistry. 40:6414–6421. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mitsuzuka K, Handa K, Satoh M, Arai Y and
Hakomori S: A specific microdomain (‘glycosynapse 3’) controls
phenotypic conversion and reversion of bladder cancer cells through
GM3-mediated interaction of alpha3beta1 integrin with CD9. J Biol
Chem. 280:35545–35553. 2005.
|
|
39
|
Rubinstein E, Le Naour F, Billard M,
Prenant M and Boucheix C: CD9 antigen is an accessory subunit of
the VLA integrin complexes. Eur J Immunol. 24:3005–3013. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kotha J, Longhurst C, Appling W and
Jennings LK: Tetraspanin CD9 regulates beta 1 integrin activation
and enhances cell motility to fibronectin via a PI-3
kinase-dependent pathway. Exp Cell Res. 314:1811–1822. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Desgrosellier JS and Cheresh DA: Integrins
in cancer: biological implications and therapeutic opportunities.
Nat Rev Cancer. 10:9–22. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shattil SJ, Kim C and Ginsberg MH: The
final steps of integrin activation: the end game. Nat Rev Mol Cell
Biol. 11:288–300. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pellinen T, Rantala JK, Arjonen A, Mpindi
JP, Kallioniemi O and Ivaska J: A functional genetic screen reveals
new regulators of beta1-integrin activity. J Cell Sci. 125:649–661.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chambrion C and Le Naour F: The
tetraspanins CD9 and CD81 regulate CD9P1-induced effects on cell
migration. PLoS One. 5:e112192010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Castro-Sanchez L, Soto-Guzman A,
Navarro-Tito N, Martinez-Orozco R and Salazar EP: Native type IV
collagen induces cell migration through a CD9 and DDR1-dependent
pathway in MDA-MB-231 breast cancer cells. Eur J Cell Biol.
89:843–852. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Murayama Y, Miyagawa J, Oritani K, et al:
CD9-mediated activation of the p46 Shc isoform leads to apoptosis
in cancer cells. J Cell Sci. 117:3379–3388. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zvereff V, Wang JC, Shun K, Lacoste J and
Chevrette M: Colocalisation of CD9 and mortalin in CD9-induced
mitotic catastrophe in human prostate cancer cells. Br J Cancer.
97:941–948. 2007.PubMed/NCBI
|
|
48
|
Shallal S and Kornbluth J: CD9 expression
enhances the susceptibility of myeloma cell lines to cell-mediated
cytolysis. Blood. 96:224–233. 2000.PubMed/NCBI
|
|
49
|
Murayama Y, Miyagawa J, Shinomura Y, et
al: Significance of the association between heparin-binding
epidermal growth factor-like growth factor and CD9 in human gastric
cancer. Int J Cancer. 98:505–513. 2002. View Article : Google Scholar
|
|
50
|
Murayama Y, Shinomura Y, Oritani K, et al:
The tetraspanin CD9 modulates epidermal growth factor receptor
signaling in cancer cells. J Cell Physiol. 216:135–143. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Qi JC, Wang J, Mandadi S, et al: Human and
mouse mast cells use the tetraspanin CD9 as an alternate
interleukin-16 receptor. Blood. 107:135–142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Atanackovic D, Hildebrandt Y, Templin J,
et al: Role of interleukin 16 in multiple myeloma. J Natl Cancer
Inst. 104:1005–1020. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hwang JR, Jo K, Lee Y, Sung BJ, Park YW
and Lee JH: Upregulation of CD9 in ovarian cancer is related to the
induction of TNF-alpha gene expression and constitutive NF-kappaB
activation. Carcinogenesis. 33:77–83. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kohmo S, Kijima T, Otani Y, et al: Cell
surface tetraspanin CD9 mediates chemoresistance in small cell lung
cancer. Cancer Res. 70:8025–8035. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer and cancer stem cells. Nature.
414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar
|
|
57
|
Kim YJ, Yu JM, Joo HJ, et al: Role of CD9
in proliferation and proangiogenic action of human adipose-derived
mesenchymal stem cells. Pflugers Arch. 455:283–296. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Biermann K, Heukamp LC, Steger K, et al:
Gene expression profiling identifies new biological markers of
neoplastic germ cells. Anticancer Res. 27:3091–3100.
2007.PubMed/NCBI
|
|
59
|
Nishida H, Yamazaki H, Yamada T, et al:
CD9 correlates with cancer stem cell potentials in human B-acute
lymphoblastic leukemia cells. Biochem Biophys Res Commun.
382:57–62. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yamazaki H, Xu CW, Naito M, et al:
Regulation of cancer stem cell properties by CD9 in human B-acute
lymphoblastic leukemia. Biochem Biophys Res Commun. 409:14–21.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ghani FI, Yamazaki H, Iwata S, et al:
Identification of cancer stem cell markers in human malignant
mesothelioma cells. Biochem Biophys Res Commun. 404:735–742. 2011.
View Article : Google Scholar : PubMed/NCBI
|
